Brought to you by 
Shield and Gemini to co-develop osteoporosis test
13 Jul 1999
Executive Summary
Shield Diagnostics (mostly cardiovascular, infectious disease, and autoimmune disease tests) and functional genomics company Gemini Holdings will co-develop a DNA test for a gene variation associated with osteoporosis.
Deal Industry
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Shield and Gemini to co-develop osteoporosis test
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice